The trademark application OTHAIR was filed by PROTHENA BIOSCIENCES LIMITED, a corporation established under the laws of Ireland (the "Applicant"). The application was published for oppositions on September 29, 2021, and it was registered by office on January 6, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and address of the trademark registration was recorded on August 22, 2021.
Goods And Services
The mark was filed in class 5 with following description of goods:
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes.
The mark was filed in class 42 with Research and development in the pharmaceutical and biotechnology fields.